Suppr超能文献

热休克蛋白90抑制剂AT13387可保护肺泡-毛细血管屏障,预防盐酸诱导的慢性肺损伤和肺纤维化。

The Heat Shock Protein 90 Inhibitor, AT13387, Protects the Alveolo-Capillary Barrier and Prevents HCl-Induced Chronic Lung Injury and Pulmonary Fibrosis.

作者信息

Colunga Biancatelli Ruben M L, Solopov Pavel, Dimitropoulou Christiana, Gregory Betsy, Day Tierney, Catravas John D

机构信息

Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk, VA 23508, USA.

School of Medical Diagnostics & Translational Sciences, College of Health Sciences, Old Dominion University, Norfolk, VA 23508, USA.

出版信息

Cells. 2022 Mar 19;11(6):1046. doi: 10.3390/cells11061046.

Abstract

Hydrochloric acid (HCl) exposure causes asthma-like conditions, reactive airways dysfunction syndrome, and pulmonary fibrosis. Heat Shock Protein 90 (HSP90) is a molecular chaperone that regulates multiple cellular processes. HSP90 inhibitors are undergoing clinical trials for cancer and are also being studied in various pre-clinical settings for their anti-inflammatory and anti-fibrotic effects. Here we investigated the ability of the heat shock protein 90 (HSP90) inhibitor AT13387 to prevent chronic lung injury induced by exposure to HCl in vivo and its protective role in the endothelial barrier in vitro. We instilled C57Bl/6J mice with 0.1N HCl (2 µL/g body weight, intratracheally) and after 24 h began treatment with vehicle or AT13387 (10 or 15 mg/kg, SC), administered 3×/week; we analyzed histological, functional, and molecular markers 30 days after HCl. In addition, we monitored transendothelial electrical resistance (TER) and protein expression in a monolayer of human lung microvascular endothelial cells (HLMVEC) exposed to HCl (0.02 N) and treated with vehicle or AT13387 (2 µM). HCl provoked persistent alveolar inflammation; activation of profibrotic pathways (MAPK/ERK, HSP90); increased deposition of collagen, fibronectin and elastin; histological evidence of fibrosis; and a decline in lung function reflected in a downward shift in pressure-volume curves, increased respiratory system resistance (Rrs), elastance (Ers), tissue damping (G), and hyperresponsiveness to methacholine. Treatment with 15 mg/kg AT13387reduced alveolar inflammation, fibrosis, and NLRP3 staining; blocked activation of ERK and HSP90; and attenuated the deposition of collagen and the development of chronic lung injury and airway hyperreactivity. In vitro, AT13387 prevented HCl-induced loss of barrier function and AKT, ERK, and ROCK1 activation, and restored HSP70 and cofilin expression. The HSP90 inhibitor, AT13387, represents a promising drug candidate for chronic lung injury that can be administered subcutaneously in the field, and at low, non-toxic doses.

摘要

盐酸(HCl)暴露会引发哮喘样病症、反应性气道功能障碍综合征和肺纤维化。热休克蛋白90(HSP90)是一种调节多种细胞过程的分子伴侣。HSP90抑制剂正在进行癌症临床试验,并且也在各种临床前环境中研究其抗炎和抗纤维化作用。在此,我们研究了热休克蛋白90(HSP90)抑制剂AT13387在体内预防HCl暴露诱导的慢性肺损伤的能力及其在体外对内皮屏障的保护作用。我们给C57Bl/6J小鼠气管内滴注0.1N HCl(2 μL/g体重),24小时后开始用溶剂或AT13387(10或15 mg/kg,皮下注射)治疗,每周给药3次;在HCl处理30天后分析组织学、功能和分子标志物。此外,我们监测了暴露于HCl(0.02 N)并用溶剂或AT13387(2 μM)处理的人肺微血管内皮细胞(HLMVEC)单层中的跨内皮电阻(TER)和蛋白质表达。HCl引发了持续性肺泡炎症;促纤维化途径(MAPK/ERK、HSP90)的激活;胶原蛋白、纤连蛋白和弹性蛋白沉积增加;纤维化的组织学证据;以及肺功能下降,表现为压力-容积曲线下移、呼吸系统阻力(Rrs)增加、弹性(Ers)增加、组织阻尼(G)增加以及对乙酰甲胆碱的高反应性增加。用15 mg/kg AT13387治疗可减轻肺泡炎症、纤维化和NLRP3染色;阻断ERK和HSP90的激活;并减轻胶原蛋白的沉积以及慢性肺损伤和气道高反应性的发展。在体外,AT13387可预防HCl诱导的屏障功能丧失以及AKT、ERK和ROCK1激活,并恢复HSP70和丝切蛋白的表达。HSP90抑制剂AT13387是一种有前景的慢性肺损伤候选药物,可在现场皮下给药,且剂量低、无毒。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20a0/8946990/c30c16043c84/cells-11-01046-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验